The BC Cancer Personalized OncoGenomics (POG) Program, co-led by Dr. Marco Marra, Director of Canada’s Michael Smith Genome Sciences Centre at BC Cancer and BC Cancer Medical Oncologist Dr. Janessa Laskin, is a patient-centric research initiative, consisting of oncologists, pathologists and other clinical, research, and technical personnel, studying the impact of embedding whole genome and transcriptome analysis into the clinical care of B.C. patients with advanced cancers.

POG is a world-leading research program that is using intensive genomic data collection and analysis to identify and better understand the genomic alterations that drive cancer growth, metastasis, and the biological evolution and response to therapies. Integration of genomic, transcriptomic, clinical, and treatment data provides a rich dataset for the interrogation and understanding of correlates of treatment response and resistance.

Analysis of the data from the first 570 patients, published in the April 2020 issue of Nature Cancer and featured on its cover, has demonstrated the impacts of therapy on cancer genomes and the potential for precision oncology to provide more effective therapeutic options for advanced cancer patients.

POG


For Patients & Public

Information and educational resources curated for patients and members of the public interested in learning more about POG.

Learn more.

For Medical Professionals

Information, educational resources, upcoming seminars and access to POG reports for medical professionals.

Learn more.

For Scientists

Information, educational resources, upcoming seminars and access to POG data for researchers.

Learn more.

POG Eligibility and Enrollment

Who is eligible for POG?

This is a highly experimental research program for cancer patients being treated and consistently followed at BC Cancer. There are many specific inclusion criteria but the main ones to consider are:

  • Patients with incurable, metastatic disease;
  • Patients with limited or no prior chemotherapy;
  • Fit and functionally well;
  • Cancer that can be easily biopsied;
  • Permanent B.C. residents receiving care and follow up in B.C.;
  • Other disease/type specific criteria may also apply to individual cases.

How do patients get enrolled in POG?

For more information on POG and eligibility, BC patients should speak to their medical oncologist at their next scheduled visit. There are many other provinces with cancer genomic studies, patients should discuss their interest in clinical trials with their medical oncologist to explore their local options.


Further questions regarding POG can be directed to: POGinfo@bcgsc.ca


CBC The Nature of Things - Cracking Cancer

CBC's The Nature of Things, one of the most successful series in Canadian TV history, featured the POG program in their episode Cracking Cancer, available here!

The POG Team

The POG team includes more than 200 oncologists, pathologist, radiologists, scientists, technicians and coordinators.
Medical Oncology

Abdul Al-Tourah

Helen Anderson

Vanessa Bernstein

Sylvie Bourque

Barbara Campling

Angela Chan

Theresa Chan

Sylvia Cheng

Kim Chi

Stephen Chia

Janine Davies

Rebecca Deyell

David Dix

Thuan Do

Bernhard Eigl

Susan Ellard

Xiaolan Feng

David Fenton

Daygen Finch

Paul Galbraith

Karen Gelmon

Alina Gerrie

Sharlene Gill

Karmjit Gill

Anagha Gurjal

Edward Hardy

Jason Hart

Cheryl Ho

Paul Hoskins

Michael Humphreys

Bal Johal

Kong Khoo

Jenny Ko

Christian Kollmannsberger

Doran Ksienski

Janessa Laskin

Lyly Le

Christopher Lee

Ursula Lee

Howard Lim

Caroline Lohrisch

Jonathan Loree

Nicol Macpherson

Barb Melosky

John Paul McGhie

Corey Metcalf

Deepu Mirchandani

Sujaatha Narayanan

Thao Nguyen

Conrad Oja

Gary Pansegrau

Maryse Power

Bradley Proctor

Sanjay Rao

Rod Rassekh

Jennifer Rauw

Daniel Renouf

Paul Rogers

David Sanford

Delia Sauciuc

Kerry Savage

Ravinder Sawhney

Asif Shaikh

Wen Wen Shan

Tamara Shenkier

Christine Simmons

Kevin Song

Caron Strahlendorf

Sophie Sun

Isabella Tai

Ann Tan

Sara Taylor

Brian Thiessen

Anna Tinker

Dorothy Uhlman

Joanna Vergidis

Diego Villa

Deepa Wadhwa

Tamana Walia

HuiLi Wong

Muhammad Zulfigar

Bioinformatics

Jianghong An

Dustin Bleile

Melika Bonakdar

Reanne Bowlby

Marc Calingo

Marcus Carreira

Simon Chan

Dean Cheng

Young Cheng

Caleb Choo

Eric Chuah

Richard Corbett

Veronika Csizmok

Anna Davies

Athena Deng

Matthew Douglas

Jasleen Grewal

Cameron Grisdale

An He

Steven Jones

Eleanor Lewis

Correy Lim

Daniel Macmillan

Alireza Heravi Moussavi

Karen Mungall

Kieran O'Neill

Diana Palmquist

Johnson Pang

Brayden Pellegrini

Erin Pleasance

Patrick Plettner

Cara Reisle

Sara Sadeghi

Yaoqing Shen

Greg Taylor

Emma Titmuss

Victoria Trinh

Kane Tse

Kathleen Wee

Laura Williamson

Tina Wong

Wei Zhang

Genome Science

Robin Coope

Peter Eirew

Bruno Grande

Martin Hirst

Rob Holt

Aly Karsan

Sreeja Leelakumari

Marco Marra

Helen McDonald

Michelle Moksa

Richard Moore

Gregg Morin

Ryan Morin

Andy Mungall

Brad Nelson

Pawan Pandoh

Kevin Sauve

Natasja Wye

Amir Zadeh

Yongjun Zhao

Pathology

Andy Churg

Christopher Dunham

Anna Lee

Pedro Farinha

Lien Hoang

Cheng-Han Lee

Nissreen Mohammad

Tony Ng

Torsten Nielsen

David Schaeffer

Brian Skinnider

Graham Slack

Basile Tessier-Cloutier

Suzanne Vercauteren

Stephen Yip

Chen Zhou


Project Management/Coordination

Cecilia Crosby

Darko Curman

Veronica Dabrowski

Balvir Deol

Nancy Ferguson

Ana Fisic

Colleen Fitzgerald

Cathy Fitzpatrick

Alexandra Fok

Colleen Jantzen

Jas Kandola

Julie Lorette

Jessica Nelson

Robyn Roscoe

June Song

Lindsay Zibrik


Scientific Advisory Committee

Lillian Siu

Elaine Mardis

Trevor Pugh

Soheil Meshinchi

Michael Berger

Ulrik Lassen

Sean Grimmond


Medical Genetics
 

Linlea Armstrong

 

Ian Bosdet

Gillian Mitchell

Sean Young

Intan Schrader


Radiology

Fergus Cafferty

David Ferguson

Colin Mar

Montgomery Martin

Ren Yuan


Clinical Genomics

Lucas Swanson

Jillian Slind

Liz Starks

Lateef Yang

Jelena Sihvonen


Social Science

Samantha Pollard

Dean Regier

Deirdre Weymann


Clinical Ethics

Alice Virani


Pharmacy

Shirin Abadi

Former POG Team Members

    

Pathology

Yazeed Alwalaie

Daiana Becker-Santos

Kathy Ceballos

Bakul Dalal

John English

Patrice Eydoux

Anthony Karnezis

Helga Klein-Parker

Lawrence Lee

Hector Li Chang

Malcolm Hayes

Tadaaki Hiruki

Hugo Horlings

David Huntsman

Nikita Makretsov

Greg Naus

Tomo Osako

Amir Rahemtulla

Brandon Sheffield

Sona Sihra

Peyman Tavassoli

Tom Thomson

Tracy Tucker

Emilija Todorovic

Dirk van Niekerk

Carlos Vilamil

Joanne Wright

Bioinformatics

Pinaki Bose

Morgan Bye

Carolyn Ch'ng

Martin Jones

Katayoon Kasaian

Ji-Young Kim

Jake Lever

Yvonne Li

William Long

Yussanne Ma

Elisa Majounie

Brandon Pierce

Nina Thiessen

Eric Zhao

Kelsey Zhu

Genome Science

Sam Aparicio

Scott Brown

Christopher Hughes

Heather Kirk

Cydney Nielsen

Julie Nielsen

Jacquie Schein

Colin Schlosser

Sohrab Shah

Project Management/Coordination

Leslie Alfaro

Charlene Appleby

Christiana Carstairs

Candace Carter

Katherine Mui

Payal Sipahimalani

Isabel Trapaga Avancena

Peggy Tsang


Medical Oncology

Winson Cheung

Joseph Connors

Donna Hogge

Hagen Kennecke

Meg Knowling

Nevin Murray


Social Science

Anita Charters

Peter Chow-White

Dung Ha


Radiology

Francois Benard

John Myo

Peer-reviewed publications

With more than 35 peer-reviewed scientific publications, findings from the POG program are influencing precision oncology approaches around the world.

POG publications


POG peer-reviewed publications

Pleasance E, Titmuss E, Williamson L et al. Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes. Nature Cancer. 2020.


Lavoie JM, Mitchell T, Lee SE et al. Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis. Investigational New Drugs. 2020.


Wong D, Shen Y, Levine AB et al. The pivotal role of sampling recurrent tumors in the precision care of patients with tumors of the central nervous system. Cold Spring Harbor Molecular Case Studies. 2019.


Williamson LM, Steel M, Grewal JK et al. Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor. Cold Spring Harbor Molecular Case Studies. 2019.


Thibodeau ML, Zhao EY, Reisle C et al. Base excision repair deficiency signatures implicate germline and somatic MUTYH aberrations in pancreatic ductal adenocarcinoma and breast cancer oncogenesis. Cold Spring Harbor Molecular Case Studies. 2019.


Majounie E, Wee K, Williamson LM et al. Fluorouracil sensitivity in a head and neck squamous cell carcinoma with a somatic DPYD structural variant. Cold Spring Harbor Molecular Case Studies. 2019.


Karasinska J, Topham JT, Kalloger SE et al. Altered gene expression along the glycolysis-cholesterol synthesis axis is associated with outcome in pancreatic cancer. Clinical Cancer Research. 2019.


Feng X, Pleasance E, Zhao EY, et al. Therapeutic implication of genomic landscape of adult metastatic sarcoma. JCO Precision Oncology. 2019.


Jones MR, Williamson LM, Topham JT, et al. NRG1 gene fusions are recurrent, clinically actionable gene rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma. Clinical Cancer Research. 2019.


Grewal JK, Tessier-Cloutier B, Jones M, et al. Application of a neural network whole transcriptome-based pan-cancer method for diagnosis of primary and metastatic cancers. JAMA Network Open. 2019.


Tsang ES, Shen Y, Chooback N, et al. Clinical outcomes after whole-genome sequencing in patients with metastatic non-small-cell lung cancer. Cold Spring Harbor Molecular Case Studies. 2019.


Ko JJ, Grewal JK, Ng T, et al. Whole-genome and transcriptome profiling of a metastatic thyroid-like follicular renal cell carcinoma. Cold Spring Harbor Molecular Case Studies. 2018.


Wong HL, Zhao EY, Jones MR, et al. Temporal dynamics of genomic alterations in a BRCA1 germline-mutated pancreatic cancer with low genomic instability burden but exceptional response to Fluorouracil, Oxaliplatin, Leucovorin, and Irinotecan. JCO Precision Oncology. 2018.


Newton Y, Rassekh RS, Deyell RJ, et al. Comparative RNA-sequencing analysis benefits a pediatric patient with relapsed cancer. JCO Precision Oncology. 2018.


Chahal M, Pleasance E, Grewal J, et al. Personalized oncogenomic analysis of metastatic adenoid cystic carcinoma: using whole-genome sequencing to inform clinical decision making. Cold Spring Harbor Molecular Case Studies. 2018.


Ronsley R, Rassekh SR, Shen Y, et al. Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma. Cold Spring Harbor Molecular Case Studies. 2018.


Owen DR, Wong HL, Bonakdar M, et al. Molecular characterization of ERBB2-amplified colorectal cancer identifies potential mechanisms of resistance to targeted therapies: a report of two instructive cases. Cold Spring Harbor Molecular Case Studies. 2018.


Thibodeau ML, Bonakdar M, Zhao E, et al. Whole genome and whole transcriptome genomic profiling of a metastatic eccrine porocarcinoma. NPJ Precision Oncology.


Zhao EY, Shen Y, Pleasance E, et al. Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer. Clinical Cancer Research. 2017.


Jones MR, Lim H, Shen Y, et al. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer. Annals in Oncology. 2017.


Wong HL, Yang KC, Shen Y, et al. Molecular characterization of metastatic pancreatic neuroendocrine tumours (PNETs) using whole genome and transcriptome sequencing. Cold Spring Harbor Molecular Case Studies. 2018.


Grewal JK, Eirew P, Jones M, et al. Detection and genomic characterization of a mammary-like adenocarcinoma. Cold Spring Harbor Molecular Case Studies. 2017.


Chooback N, Shen Y, Jones M, et al. Carcinoma ex pleomorphic adenoma: case report and options for systemic therapy. Current Oncology. 2017.


Chow-White P, Ha D, Laskin J, et al. Knowledge, attitudes, and values among physicians working with clinical genomics: a survey of medical oncologists. Human Resources for Health. 2017.


Thibodeau ML, Reisle C, Zhao E, et al. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline CHEK2:c.1100delC mutation and a concomitant diagnosis of metastatic invasive ductal breast carcinoma. Cold Spring Harbor Molecular Case Studies. 2017.


Weymann D, Laskin J, Roscoe R, et al. The cost and cost-trajectory of whole-genome analysis guiding treatment of patients with advanced cancer. Molecular Genetetics and Genomic Medicine. 2017.


Sheffield BS, Tessier-Cloutier B, Li-Chang H, et al. Personalized oncogenomics in the management of gastrointestinal carcinomas-early experiences from a pilot study. Current Oncology. 2016.


Laskin J, Ha D, Chan T, et al. Clinicians identify high need to increase their genomic literacy to applied cancer genomics. Annals of Oncology. 2016.


Sheffield BS, Fulton R, Kalloger SE, et al. Investigation of PD-L1 biomarker testing methods for PD-1 axis inhibition in non-squamous non-small cell lung cancer. Journal of Histochemistry and Cytochemistry. 2016.


Alassiri AH, Ali RH, Shen Y, et al. ETV6-NTRK3 is expressed in a subset of ALK-negative inflammatory myofibroblastic tumors. The American Journal of Surgical Pathology. 2016.


Jones, MR, Schrader KA, Shen Y, et al. Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancer. Annals of Oncology. 2016.


Parker JD, Shen Y, Pleasance E, et al. Molecular etiology of an indolent lymphoproliferative disorder determined by whole-genome sequencing. Cold Spring Harbor Molecular Case Studies. 2016.


Laskin J, Jones S, Aparicio S, et al. Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers. Cold Spring Harbor Molecular Case Studies. 2015.


Bose, P, Pleasance ED, Jones M, et al. Integrative genomic analysis of ghost cell odontogenic carcinoma. Oral Oncology. 2015.


Sheffield BS, Tinker AV, Shen Y, et al. Personalized oncogenomics: clinical experience with malignant peritoneal mesothelioma using whole genome sequencing. PLoS One. 2015.


Jamshidi F, Pleasance E, Li Y, et al. Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. Oncologist. 2014.


Jones SJ, Laskin J, Li YY, et al. Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors. Genome Biology. 2010.


POG-associated peer-reviewed publications

Chan-Seng-Yue M, Kim JC, Wilson GW et al. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Nature Genetics. 2020.


Vaske OM, Bjork I, Salama SR et al. Comparative tumor RNA sequencing analysis for difficult-to-treat pediatric and young adult patients with cancer. JAMA Network Open. 2019.


Pandoh PK, Corbett RD, McDonald H et al. A high-throughput protocol for isolating cell-free circulating tumor DNA from peripheral blood. BioTechniques. 2019.


Haile S, Corbett RD, Bilobram S et al. Evaluation of protocols for rRNA depletion-based RNA sequencing of nanogram inputs of mammalian total RNA. PLoS One. 2019.


Haile S, Corbett RD, Bilobram S et al. Sources of erroneous sequences and artifact chimeric reads in next generation sequencing of genomic DNA from formalin-fixed paraffin-embedded samples. Nucleic Acids Research. 2019.


Haile S, Pandoh PK, McDonald H et al. Automated high throughput nucleic acid purification from formalin-fixed paraffin-embedded tissue samples for next generation sequence analysis. PLoS One. 2017.


Peer-reviewed publications citing POG

Belli V et al. Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models. Journal of Experimental and Clinical Cancer Research. 2019.


Pantziarka P, Meheus L. Omics-driven drug repurposing as a source of innovative therapies in rare cancers. Expert Opinions on Orphan Drugs. 2018.


Pantziarka P, Bouche G, André N. “Hard” drug repurposing for precision oncology: the missing link? Frontiers in Pharmacology. 2018.


Berger MF, Mardis ER. The emerging clinical relevance of genomics in cancer medicine. Nature Reviews in Clinical Oncology. 2018.  


Funders & Partners

The Personalized OncoGenomics (POG) Program would not be possible without the support of our funders and collaborating partners.

POG is pleased to announce that it is a member of the International Cancer Genome Consortium — Accelerating Research in Genomic Oncology (ICGC-ARGO).

We gratefully acknowledge all funders and supporting partners of the BC Cancer Genome Sciences Center and the development of the Personalized OncoGenomics Program.

FUNDERS

This work would not be possible without the generous support of the following organizations: BC Cancer FoundationGenome British ColumbiaGenome CanadaCanada Foundation for InnovationBC Knowledge Development Fund (Government of British Columbia), The Cancer Genome Atlas (TCGA) Program (National Cancer Institute (NCI), National Human Genome Research Institute (NHGRI)), The Genotype-Tissue Expression (GTEx) Project (National Institutes of Health (NIH))

 

PARTNERS

Thank you to the following organizations who support our work: Centre for Clinical Genomics (CCG)International Cancer Genome Consortium — Accelerating Research in Genomic Oncology (ICGC-ARGO)BC Cancer Hereditary Cancer Program (HCP)Enhanced Pancreatic Cancer Profiling for Individualized Care (EPPIC) (Terry Fox Translational Research Program), Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis (PanGen) (BC Cancer, Terry Fox Research Institute (TFRI), Pancreas Centre BC), PRecision Oncology For Young peopLE (PROFYLE) (Terry Fox Research Institute (TFRI)), Terry Fox Designated Canadian Comprehensive Cancer Centres Network (TF4CN) (Princess Margaret Cancer Centre, Terry Fox Research Institute (TFRI), BC Cancer), Canadian Distributed Infrastructure for Genomics (CanDIG)Treehouse Childhood Cancer InitiativeGilead Sciences.


Associated Programs

The POG program interfaces with various clinical programs and trails. Learn more about these programs here:

PanGen

Terry Fox PROFYLE

BC Cancer Hereditary Cancer Program

CanDIG

ICGC ARGO


Contact Us

For more information: POGinfo@bcgsc.ca

Back to top